These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17028042)

  • 21. Preliminary Examination of an Appropriate Price Calculation Method and Medical Treatment Costs for Foreign Visitors in Japan.
    Takura T; Study Group Research On Appropriate Medical Treatment Prices For Foreigners Visiting Japan
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34072299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness as a price control.
    Jena AB; Philipson T
    Health Aff (Millwood); 2007; 26(3):696-703. PubMed ID: 17485746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fair deal: local factors add to price of supplies.
    Carr A
    Nature; 2004 Jun; 429(6992):601. PubMed ID: 15190326
    [No Abstract]   [Full Text] [Related]  

  • 24. Shelf price agreements: a novel approach to competitive bidding for arrhythmia therapy devices.
    Keast RK; Pelosi F; Morady F; Larin LR; Goldstein-Dunn J; Cox D; Michalak CG; Fetyko S; Denton TA; Eagle KA
    J Cardiovasc Manag; 2004; 15(5):12-5. PubMed ID: 15506010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No fix needed. Price transparency for medical devices a nonsolution for a nonproblem.
    Ubl S
    Mod Healthc; 2012 Mar; 42(11):34-5. PubMed ID: 22462322
    [No Abstract]   [Full Text] [Related]  

  • 27. Industry economics in the United States.
    Med Device Technol; 2004 Apr; 15(3):34-6. PubMed ID: 15255538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seeing is believing: materials stance on price transparency.
    DeJohn P
    Mater Manag Health Care; 2008 Feb; 17(2):24-8. PubMed ID: 18390283
    [No Abstract]   [Full Text] [Related]  

  • 29. US market: 2008 priorities.
    Novelli T
    Med Device Technol; 2008; 19(3):58. PubMed ID: 18557412
    [No Abstract]   [Full Text] [Related]  

  • 30. Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?
    Tamura M; Nakano S; Sugahara T
    Int J Health Plann Manage; 2019 Apr; 34(2):583-593. PubMed ID: 30549085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping your competitive position.
    D'Aveni RA
    Harv Bus Rev; 2007 Nov; 85(11):110-20, 154. PubMed ID: 18159791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A competitive model for supply of materials for hemodynamics].
    Bozzi G; Zerega G
    G Ital Cardiol; 1998 Feb; 28(2):140-7. PubMed ID: 9534054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Price survey. PTCA prices heading up again.
    Hosp Mater Manage; 2003 Aug; 28(8):1, 12-5. PubMed ID: 12920777
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical device distribution: today and tomorrow.
    Widensohler S
    Med Device Technol; 2000; 11(6):34-6. PubMed ID: 15326792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The myth of group buying leverage.
    Krauss KR
    Health Ind Today; 1987; 50(11):20-3. PubMed ID: 10302082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New purchasing measures for stellar performance.
    Harding M
    Hosp Mater Manage Q; 1998 Nov; 20(2):67-71. PubMed ID: 10339182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical packaging: more for less?
    Andrews J; Hunt N
    Med Device Technol; 1999 Apr; 10(3):26-8. PubMed ID: 10387624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How cheap are Canada's drugs really?
    Hollis A
    J Pharm Pharm Sci; 2004 Jun; 7(2):215-6. PubMed ID: 15367378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
    Danzon PM; Wang YR; Wang L
    Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of deregulation on the prices of nicotine replacement therapy products in Finland.
    Aalto-Setälä V; Alaranta A
    Health Policy; 2008 May; 86(2-3):355-62. PubMed ID: 18207603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.